相关实验视频

Updated: Jul 14, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

CD22是CAR-NK细胞治疗食道状细胞癌的潜在目标

Tingdang Liu¹, Ximing Dai¹, Yien Xu^1,2

¹Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China.

Journal of translational medicine

|October 11, 2023

概括

化学抗原受体NK (CAR-NK) 细胞疗法对食道状细胞癌 (ESCC) 显示出前景. 研究人员将CD22确定为潜在的标,证明CD22向的CAR-NK细胞有效地抑制ESCC细胞生长.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
细胞疗法细胞疗法

背景情况:

化学抗原受体NK (CAR-NK) 细胞疗法是一种有前途的免疫疗法,在血液恶性瘤中取得了成功.
固体瘤,包括食道状细胞癌 (ESCC),由于抗原稀缺和复杂的瘤微环境,成功率有限.
这项研究调查了在血液癌症中已知的标记物CD22,作为ESCC中CAR-NK细胞治疗的潜在标.

研究的目的:

在ESCC中确定CAR-NK细胞治疗的潜在细胞表面标.
评估ESCC中CD22的表达及其与临床参数的相关性.
评估针对CD22向的CAR-NK细胞对ESCC的疗效.

主要方法:

在癌症基因组图谱 (TCGA) 数据库中对13种瘤表面抗原的分析.
定量实时PCR (qCPR) 用于ESCC细胞系和患者样本中的mRNA表达.
免疫光 (IF) 和免疫组织化学 (IHC) 检测ESCC细胞系和患者样本中的CD22表达.
CD22表达和临床参数之间的相关性分析.
使用实时细胞分析仪 (RTCA) 对针对CD22的CAR-NK细胞进行体外疗效评估.

主要成果:

在ESCC细胞系 (KYSE-140,KYSE-150) 的表面表达了CD22.
免疫组织化学检测显示,在87名ESCC患者样本中,CD22的阳性率为80.46%,膜表达率为27.59%.
在ESCC中,CD22表达与淋巴结转移相关.
改造的CD22向的CAR-NK细胞对ESCC细胞系产生显著的抑制作用 (p < 0.0001).

结论:

CD22是ESCC中CAR-NK细胞治疗的可行的瘤表面抗原标.
反CD22CAR表达性免疫细胞为ESCC提供了潜在的治疗策略.
CD22 CAR-NK 细胞在其他癌症中可能具有更广泛的应用,因此需要进一步的体内研究.

关键词:

在CAR-NK细胞疗法中.在CD2222中,我们可以看到CD22.食管状细胞癌的癌症.免疫治疗是一种免疫疗法.固体瘤是一个固体瘤.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...